Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Clinical Trial ID NCT00688194

PubWeight™ 4.41‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00688194

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011 2.10
2 Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012 0.79
3 Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) 2011 0.79
4 Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol 2010 0.79
Next 100